CriticalAntidepressants. Other antidepressants of herbal origin×Second-generation systemic triazole antifungal
Updated · Methodology
Mechanism
The liver enzymes CYP3A4 and CYP3A5 take part in isavuconazole metabolism, so medicines that induce these enzymes can lower its blood levels (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). The isavuconazole SmPC classes St John's wort as a strong inducer of these enzymes: the combination has not been studied, but isavuconazole levels may fall significantly (isavuconazole SmPC, EMA, section 4.5; isavuconazole label, US Food and Drug Administration, FDA, section 4). Hyperforin in St John's wort induces CYP3A4, CYP2B6, CYP2C9, CYP2C19 and the transporter P-glycoprotein in a dose-dependent way (St John's wort herbal monograph, EMA, sections 4.5 and 5.2). According to the Spanish St John's wort SmPC, medicines metabolised through CYP3A4 may then reach lower levels and have a reduced therapeutic effect (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).
Symptoms
The combination itself usually causes no symptoms: isavuconazole blood levels may fall significantly (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5), and its therapeutic effect may be reduced (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Isavuconazole is used for invasive aspergillosis and for mucormycosis when amphotericin B is not appropriate (isavuconazole SmPC, EMA, section 4.1). A weaker antifungal effect shows only as an infection that responds less well to treatment.
Management
The combination is contraindicated: St John's wort is on the list of strong CYP3A4/5 inducers that must not be given with isavuconazole (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.3 and 4.5; isavuconazole label, US Food and Drug Administration, FDA, sections 4 and 5.5). The contraindication does not depend on the St John's wort dose. The EMA herbal monograph does not name isavuconazole. It calls for special care with all medicines whose metabolism depends on CYP3A4. For traditional use products with a daily hyperforin intake of up to 1 mg, taken for no longer than 2 weeks, it reports no clinically relevant interactions (St John's wort herbal monograph, EMA, section 4.5). This exception does not change the contraindication in the isavuconazole documents. The Spanish St John's wort SmPC does not name isavuconazole either (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The authorisation of that product has been suspended since 11 June 2026. The isavuconazole documents do not say how long to wait between the last dose of St John's wort and the start of isavuconazole. According to the monograph, increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: European Union herbal monograph on Hypericum perforatum L., herba – Revision 1 (EMA/HMPC/7695/2021) (2022)– EMA, Committee on Herbal Medicinal Products (HMPC), European Union herbal monograph on Hypericum perforatum L., herba, Final – Revision 1, EMA/HMPC/7695/2021, 23.11.2022 (publicada 22.02.2023), secciones 4.1, 4.3 y 4.5
- AEMPS: Ficha técnica: Hipérico (nº registro 79963), sección 4.5 (2025)– AEMPS, CIMA, Hipérico Arkopharma cápsulas duras (Arkopharma), nº registro 79963, revisión 11/2025 (texto de septiembre de 2016), secciones 4.3, 4.5 y 5.2; autorización suspendida desde el 11/06/2026, no hay otra ficha técnica de hipérico vigente en CIMA
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.3 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4 y 4.5